An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Int J Clin Pharmacol Ther
; 59(12): 775-779, 2021 Dec.
Article
in En
| MEDLINE
| ID: mdl-34503643
ABSTRACT
BACKGROUND:
Fluoropyrimidines 5-fluorouracil (5-FU) and capecitabine are antimetabolite drugs used for the treatment of colorectal, breast, head, and neck malignancies. Different clinical manifestations of fluoropyrimidine-induced cardiotoxicity (FIC) have been reported in the literature. CASE REPORT A 46-year-old female patient with a history of colorectal adenocarcinoma presented to the Emergency Department due to chest pain and mildly elevated cardiac serum troponin levels. Three days earlier, she had received a first adjuvant chemotherapy treatment with oral capecitabine. After the exclusion of obstructive coronary artery disease (CAD), acute myopericarditis was suspected.CONCLUSION:
Capecitabine-induced myopericarditis is an extremely rare but important clinical condition to be recognized and treated promptly in order to prevent potentially lethal consequences of cardiac dysfunction.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Fluorouracil
/
Heart Diseases
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Int J Clin Pharmacol Ther
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2021
Document type:
Article